MACROGENICS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against MacroGenics, Inc. and Encourages Investors to Contact the Firm

Core Insights - MacroGenics announced five fatal outcomes in its TAMARACK Phase 2 study of vobramitamab duocarmazine for metastatic castration-resistant prostate cancer, leading to a significant decline in share price [1] - The share price dropped by $11.36, or approximately 77.4%, from $14.67 on May 9, 2024, to close at $3.31 on May 10, 2024 [1] Legal Actions - A class action lawsuit has been filed against MacroGenics in the United States District Court for the District of Maryland, representing all individuals and entities who acquired MacroGenics securities between March 7, 2024, and May 9, 2024 [4] - Investors have until September 24, 2024, to apply to be appointed as lead plaintiff in the lawsuit [4] - The lawsuit alleges that MacroGenics made material misrepresentations by providing overly positive statements while concealing adverse facts related to early interim safety data from the TAMARACK Phase 2 study [6]